ICU Medical, Inc. (NASDAQ:ICUI) Receives $175.67 Consensus Target Price from Analysts

ICU Medical, Inc. (NASDAQ:ICUI) has earned a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $175.6667.

ICUI has been the topic of a number of recent research reports. Piper Sandler increased their price target on ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Wall Street Zen cut shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a report on Wednesday, October 8th. Finally, KeyCorp increased their price objective on shares of ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a research note on Friday, November 7th.

Insider Buying and Selling at ICU Medical

In other news, Director Elisha W. Finney sold 1,285 shares of ICU Medical stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $140.42, for a total value of $180,439.70. Following the transaction, the director directly owned 3,995 shares in the company, valued at approximately $560,977.90. This trade represents a 24.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Virginia Ruth Sanzone sold 930 shares of the business’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $142.34, for a total value of $132,376.20. Following the completion of the transaction, the vice president directly owned 5,456 shares of the company’s stock, valued at approximately $776,607.04. The trade was a 14.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.50% of the stock is currently owned by company insiders.

Institutional Trading of ICU Medical

Several hedge funds have recently modified their holdings of the company. EP Wealth Advisors LLC purchased a new stake in shares of ICU Medical during the first quarter valued at $479,000. Vident Advisory LLC acquired a new stake in ICU Medical during the 1st quarter worth about $270,000. Simon Quick Advisors LLC purchased a new stake in ICU Medical during the 2nd quarter valued at about $275,000. AlphaQuest LLC increased its holdings in shares of ICU Medical by 3,058.3% in the second quarter. AlphaQuest LLC now owns 1,516 shares of the medical instruments supplier’s stock valued at $200,000 after purchasing an additional 1,468 shares during the period. Finally, Woodline Partners LP raised its stake in shares of ICU Medical by 31.6% in the first quarter. Woodline Partners LP now owns 160,910 shares of the medical instruments supplier’s stock worth $22,344,000 after purchasing an additional 38,671 shares during the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Price Performance

Shares of ICUI stock opened at $147.06 on Thursday. The company has a market capitalization of $3.63 billion, a P/E ratio of -474.36 and a beta of 0.82. The company’s 50-day simple moving average is $136.71 and its two-hundred day simple moving average is $130.20. ICU Medical has a one year low of $107.00 and a one year high of $175.51. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.45 and a quick ratio of 1.19.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.43 by $0.60. The firm had revenue of $533.30 million during the quarter, compared to analyst estimates of $511.46 million. ICU Medical had a positive return on equity of 7.71% and a negative net margin of 0.32%.ICU Medical’s quarterly revenue was down 8.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.59 earnings per share. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. As a group, equities analysts anticipate that ICU Medical will post 4.11 EPS for the current year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.